Claim your 30% discount on Global Market Reports with code ONLINE30. Limited time only.

Claim your 30% discount on Global Market Reports with code ONLINE30. Limited time only.

What Are the Latest Market Insights for the End Stage Renal Disease (ESRD) Drug Industry?

Recent years have seen a significant expansion in the market size of the end stage renal disease (esrd) drug. The market is expected to balloon from $131.41 billion in 2024 to $148.55 billion in 2025, representing a compound annual growth rate (CAGR) of 13.0%. This surge in the past period can be credited to various factors including the rising incidences of end stage renal disease, an aging population demographic, enhanced accessibility to healthcare services, strategic government initiatives and policies, along with an increased uptake of renal replacement therapies.

In the upcoming years, a swift expansion is predicted for the market size of end stage renal disease (esrd) drugs, with an projected growth to $262.76 billion by 2029, displaying a compound annual growth rate (CAGR) of 15.3%. This growth rate during the forecast period can be credited to the advent of new therapies and drug innovations, amplified health care spending, escalating global incidence of chronic kidney diseases, personalized treatment strategies, regulatory backing, and fast-tracked endorsements. Key trends for this forecasting period consist of an escalating occurrence of end stage renal disease, improvements in treatment methods, a rising focus on precision medicine, the progress of combination therapies, and the incorporation of technology in healthcare.

Download The Free Sample Report Here:

https://www.thebusinessresearchcompany.com/sample.aspx?id=9437&type=smp

What Forces Are Driving The Growth Of The End Stage Renal Disease (ESRD) Drug Industry?

The surge in obesity and diabetes cases is anticipated to fuel the expansion of the end-stage renal disease (ESRD) drug market. Obesity refers to an abnormal or excessive accumulation of fat that poses a health risk, while diabetes is a chronic illness characterized by the pancreas’ inability to produce adequate insulin or the body’s inefficient use of the produced insulin. For patients suffering from renal disease, fluid and electrolyte level management, blood pressure regulation, and elimination of waste products via dialysis can enhance overall health and wellness. This could potentially lead to weight loss and better blood sugar control. For example, World Obesity, a U.S.-based membership organization dedicated to the study and management of obesity, projected in March 2022 that the number of obese individuals could escalate to 892 million in 2025 and further to 1,025 million in 2030. Moreover, the National Health Service in the UK, a publicly funded healthcare system, estimated in February 2023 that by 2030, around 5.5 million people in the UK, nearly 9% of the population, could be diagnosed with diabetes. Consequently, the upswing in obesity and diabetes cases will boost the end-stage renal disease (ESRD) drug market.

What Is The Overview Of Market Segmentation In The End Stage Renal Disease (ESRD) Drug Industry?

The end stage renal disease (esrd) drug market covered in this report is segmented –

1) By Product Type: Calcimimetics, Vitamin D, Sterols, Potassium Binders, Calcium-Based Phosphate Binders, Other Products

2) By Indication: End Stage Renal Disease (ESRD) Induced Hyperparathyroidism, End Stage Renal Disease (ESRD) Induced Hyperphosphatemia, End Stage Renal Disease (ESRD) Induced Hyperkaliemia

3) By Distribution Channel: Hospital Pharmacy, Online Pharmacy, Retail Pharmacy

4) By End User: Hospitals, Homecare, Specialty Clinics, Other End Users

Subsegments:

1) By Calcimimetics: Cinacalcet, Etelcalcetide

2) By Vitamin D: Calcitriol, Doxercalciferol, Paricalcitol

3) By Sterols: Ergocalciferol, Cholecalciferol

4) By Potassium Binders: Sodium Polystyrene Sulfonate, Patiromer, Sodium Zirconium Cyclosilicate

5) By Calcium-Based Phosphate Binders: Calcium Acetate, Calcium Carbonate

6) By Other Products: Iron Supplements, Erythropoiesis-Stimulating Agents

What Future Market Trends Are Projected For The End Stage Renal Disease (ESRD) Drug Industry?

Strategic product advancements are emerging as a significant trend for achieving market traction in the end-stage renal disease (ESRD) drug market. The leading companies in the ESRD drug market are resorting to the development of groundbreaking solutions to maintain their market foothold. For instance, in April 2022, GlaxoSmithKline PLC, a biotech and pharmaceutical company located in the UK, confirmed that the New Drug Application (NDA) for daprodustat, an oral hypoxia-inducible factor prolyl hydroxylase inhibitor (HIF-PHI) potentially used for treating chronic kidney disease anemia (CKD), was accepted by the US Food and Drug Administration (FDA). This novel product is built upon the unique, Nobel prize-winning research that validated how cells detect and accommodate to the presence of oxygen.

Who Are The Primary Players Operating Across The Global End Stage Renal Disease (ESRD) Drug Market?

Major companies operating in the end stage renal disease (ESRD) drug market include Pfizer Inc., AstraZeneca plc, Sanofi SA, Astellas Pharma Inc., Novartis AG, Fresenius SE & Co. KGaA, Takeda Pharmaceutical Company Limited, F. Hoffmann-La Roche Ltd., Kissei Pharmaceutical Co. Ltd., Baxter International Inc., AbbVie Inc., Amgen Inc., Akebia Drugs Inc., Bayer AG, Bristol-Myers Squibb Company, B. Braun SE, Asahi Kasei Medical Co. Ltd., Nikkiso Co. Ltd., Abbott Laboratories, Merck Co. & KGaA

Get The Full Report Here:

https://www.thebusinessresearchcompany.com/report/end-stage-renal-disease-esrd-drug-global-market-report

Which Region Offers The Most Growth Potential For The End Stage Renal Disease (ESRD) Drug Market Through 2029?

North America was the largest region in the end stage renal disease (ESRD) drug market in 2024. The regions covered in the end stage renal disease (ESRD) drug market report are Asia-Pacific, Western Europe, Eastern Europe, North America, South America, Middle East, Africa

Request For A Customized Report:

https://www.thebusinessresearchcompany.com/customise?id=9437&type=smp

About The Business Research Company:

With over 15000+ reports from 27 industries covering 60+ geographies, The Business Research Company has built a reputation for offering comprehensive, data-rich research and insights. Armed with 1,500,000 datasets, the optimistic contribution of in-depth secondary research, and unique insights from industry leaders, you can get the information you need to stay ahead in the game.

Get in touch with us:

The Business Research Company: https://www.thebusinessresearchcompany.com/

Americas +1 310-496-7795

Asia +44 7882 955267 & +91 8897263534

Europe +44 7882 955267

Email us at info@tbrc.info

Follow us on:

LinkedIn: https://in.linkedin.com/company/the-business-research-company

YouTube: https://www.youtube.com/channel/UC24_fI0rV8cR5DxlCpgmyFQ

Global Market Model: https://www.thebusinessresearchcompany.com/global-market-model